

**8th International Workshop on Waldenström's Macroglobulinemia
& Symposium on Advances in Multiple Myeloma (IWWM8)**

Wednesday, August 13, 2014

3:00-6:00 **Registration**

Thursday, August 14, 2014

Session 1	Genetic Basis of WM I		Chair: Nikhil Munshi
8:00	Zachary Hunter	USA	Genomic Landscape of WM
8:15	Marzia Varettoni	Italy	MYD88 L265P in IgM MGUS and WM
8:30	Xavier Leleu	France	MYD88 L265P in WM and related disorders
8:45	Bruno Paiva	Spain	Phenotypic and Genomic Evolution from MGUS to WM
9:00	Discussion Session		
9:30	Coffee/Tea Break		
Session 2	Genetic Basis of WM II		Chair: Linda Pilarski
10:00	Keisuke Horikawa	Australia	Consequences of MYD88 mutations in B cells
10:15	Alessandra Trojani	Italy	Gene expression profiling of WM and IGM MGUS
10:30	Stephanie Poulain	France	SNP array studies in WM
10:45	Steve Treon	USA	Clinical implications of MYD88 and CXCR4 mutations
11:00	Nikhil Munshi	USA	Comparative genomics of MM and WM
11:15	Discussion Session		
11:45	Lunch Break		
12:00-1:45	Great Debates in Multiple Myeloma Chairs: Kenneth C. Anderson Should patients with high risk smoldering myeloma receive treatment? Yes: Ola Landgren (USA) No: Morie Gertz (USA) Should triple therapy be the gold standard for frontline myeloma? Yes: Nikhil Munshi (USA) No: Meletios Dimopoulos (Greece)		Should autologous transplant be offered as consolidation to all eligible patients? Yes: Bart Barlogie (USA) No: JP Fermand (France) Should pomalidomide or carfilzomib be the initial salvage treatment in myeloma? Pomalidomide: Xavier Leleu (France) Carfilzomib: Philippe Moreau (France)
Session 3	Signaling in WM		Chair: Claudio Sette
2:00	Claudio Sette	Italy	MYD88: Opportunities for Targeting WM
2:15	Guang Yang	USA	MYD88 Pathway Signaling in WM
2:30	Yang Cao	USA	CXCR4 Pathway Signaling in WM
2:45	Stephen Ansell	USA	IGM related signaling in WM
3:00	Discussion Session		
Session 4	Origin of the WM Cell		Chair: Surinder Sahota
3:30	Linda Pilarski	Canada	Origins of WM: Implications from Genetic Analysis

3:45	Ramón García Sanz	Spain	Does the immunophenotype of WM support a memory B-cell origin for WM?
4:00	Loizos Petrikkos	Greece	IgH Clonotypic sequence analysis and its support in WM
4:15	Surinder Sahota	UK	Phenotypic and genotypic evidence in tracing the cell of origin in WM.
4:30	Discussion Session		
5:00	Day Highlights (Roger Owen, Workshop Co-Chair)		
7:00-11:00	Opening Ceremonies: Thames River Cruise/Dinner Reception (<i>Ticketed Event</i>) Special Guest Speaker: TBA Robert A. Kyle Award Ceremony		
Friday, August 15, 2014			
Session 5	Diagnosis of WM		Chair: Robert A. Kyle
8:00	Roger Owen	UK	WM/LPL in the era of molecular diagnostics
8:15	Robert Kyle	USA	Where does IgM MGUS end and WM begin?
8:30	Lian Xu	USA	PB MYD88 testing for WM diagnosis
8:45	Ranjana Advani	USA	NCCN Diagnostic & Treatment Guidelines for WM
9:00	Discussion Session		
9:30	Coffee/Tea Break		
Session 6	WM Predisposition		Chair: Mary McMaster
10:00	Ola Landgren	USA	MGUS Predispositions
10:15	Mary McMaster	USA	Familial Studies in WM and IgM MGUS
10:30	H. Ögmundsdóttir	Iceland	Familial Studies in Iceland
10:45	Sigurdur Kristinsson	Iceland	Risk factors and outcome in WM/LPL
11:00	Discussion Session		
11:30	Lunch Break		
11:45-1:45	Great Debates in Waldenstrom's Macroglobulinemia Chairs: Veronique Leblond (France) and Shirley D'Sa (UK)		
	Should MYD88 and CXCR4 be tested in all WM patients? Yes: Xavier Leleu (France) No: Eva Kimby (Sweden)		Should carfilzomib be given instead of bortezomib for WM? Yes: Irene Ghobrial (USA) No: Meletios Dimopoulos (Greece)
	Should bendamustine or ibrutinib be the first salvage in WM? Bendamustine: Mathias Rummel (Germany) Ibrutinib: Lia Palomba (USA)		Are response criteria for WM adequate? Yes: Roger Owen (UK) No: Enrica Morra (Italy)
Session 7	Novel Drug Development for WM		Chair: Steven T. Pals
2:00	Xia Liu	USA	Direct Targeting in MYD88
2:15	Sara Buhrlage	USA	IRAK pathway inhibitors
2:30	Steven Pals	Netherlands	Targeting cell adhesion and migration in WM

2:45	Aldo Roccaro	USA	CXCR4 targeted therapy
3:00	Discussion Session		
Session 8	Prognostication and Survival in WM		Chair: Ola Landgren
3:30	Pierre Morel	France	Prognostication in the era of molecular markers
3:45	Stathis Kastritis	Greece	Competing risk factors for survival in WM
4:00	Jorge Castillo	USA	Improvements in WM survival by SEER
4:15	Discussion Session		
4:45	Day Highlights (Shirley D'Sa, Workshop Co-Chair)		
Session 9 4:00-7:00 5:00-7:00	Poster Viewing Oral [13] & Poster [36] Discussion Session of Invited Abstracts		Chairs: Roger Owen & Charalampia Kyriakou
5:15-6:39	Oral Presentations		
5:15	E.L. Smith	USA	Poster W8 ; CD19 Targeted chimeric antigen modified T-cells for the treatment of WM
5:22	V. Steingrimsson	Iceland	Poster W26 ; Population based study on the impact of familial form of WM on overall survival
5:29	A. Wechalekar	UK	Poster W34 ; Characteristics and outcomes of IgM associated systemic AL amyloidosis-analysis of a prospective study [ALChem Study]
5:36	J. Paludo	USA	Poster W36 ; Clinical features and survival outcome of young patients with WM
5:43	P. Milani	Italy	Poster W21 ; Bendamustine is a well tolerated and effective rescue agent in AL amyloidosis, particularly in patients with WM
5:50	I. Ghobrial	USA	Poster W24 ; Clinical profile of single-agent modified-release oprozomib tablets in patients with WM: updated results from a multicenter, open-label, dose escalation, phase 1b/2 study
5:57	J. Nielsen	Canada	Poster W1 ; MYD88 L265P: A target for T cell based therapy of WM
6:04	L. Simon	France	Poster W6 ; Bing Neel Syndrome: the French experience
6:11	W. Jiang	USA	Poster W16 ; IMO-8400 inhibits MYD88 L265P mediated signaling and Cell growth in WM
6:18	K. Argyropoulos	USA	Poster W22 ; Multi-parameter single cell phospho-filing of the BCR signaling pathway in WM
6:25	S. Guidez	France	Poster W27 ; Prognostic importance of the quality of response to first line therapy in patients with WM
6:32	M. Fulciniti	USA	Poster W28 ; Critical growth and survival role of miR-23b/Sp1/NFkB pathway in WM
6:39	D. Joshua	Australia	Poster W31 ; Tumor induced immunosuppression in WM and MM. Marked differences in immune homeostatic balance between tumor and host
Saturday, August 16, 2014			
Session 10	Current Therapy of WM		Chair: Enrica Morra
8:00	Véronique Leblond	France	Nucleoside Analogues
8:15	Christian Buske	Germany	Alkylator Based Therapy (Excluding Bendamustine)
8:30	Mathias Rummel	Germany	Bendamustine
8:45	M. Dimopoulos	Greece	Proteasome Inhibitors
9:00	Steven Treon	USA	Ibrutinib and other Signal Inhibitors
9:15	Discussion Session		
9:45	Coffee/Tea Break		
Session 11	Treatment Considerations in WM		Chair: Meletios Dimopoulos
10:15	Irene Ghobrial	USA	Integrating signal inhibitors into WM therapy

10:30	Sandra Kanan	USA	Rituximab intolerance and alternatives in WM
10:45	Giampaolo Merlini	Italy	Diagnosis and workup of the patient with amyloidosis
11:00	Chara Kyriakou	UK	Optimal timing for stem cell transplant in WM
11:15	Enrica Morra	Italy	Long term toxicity of therapy in WM
11:30	Discussion Session		
12:00	Lunch		
12:15-12:45	Special Lecture: Shirley D'Sa (UK)		“Current Treatment Approaches to Waldenström’s macroglobulinemia in the United Kingdom”
Session 12	Special Topics in WM		Chair: Morie Gertz
1:00	Jean-Paul Fermand	France	Etiologies and Interventions for renal failure in WM
1:15	Marvin Stone	USA	Cryoglobulinemia: When to suspect and how to manage in WM
1:30	Sigbjorn Berentsen	Norway	Cold Agglutinin disease and WM: Time for divorce?
1:45	Michael Lunn	UK	Diagnosis and Management of Peripheral Neuropathy in WM and IgM related disorders
2:00	Monique Minnema	Netherlands	Diagnostic and treatment challenges with Bing Neel Syndrome
2:15	Evangelos Terpos	Greece	Coagulopathies and acquired VW deficiency in WM
2:30	Morie Gertz	USA	ASCT in the WM patient with amyloidosis
2:45	Discussion Session		
3:15	Day Highlights & Conference Adjourn (Chara Kyriakou, Workshop Co-Chair)		